Emergent buys ABEC bioreactor to transfer raxibacumab to Baltimore facility

By Gareth Macdonald 

Bioterrorism countermeasure manufacturer Emergent Biosciences has bought a 4,000L bioreactor developed by ABEC.

Read the article.

 

 

ABEC 4,000 Liter Single-Use Bioreactor to Expand Emergent BioSolutions Manufacturing Capability

Bethlehem, PA, USA, October 24, 2017- ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that Emergent BioSolutions will equip their Baltimore, Maryland bulk manufacturing facility (Bayview), designated a Center for Innovation in Advanced Development and Manufacturing (CIADM), with an ABEC 4,000L CSR bioreactor. The system will be custom designed to Emergent’s process needs, operational requirements, and facility constraints, and will greatly expand cell culture capacity at the Bayview site.